SCHEMBL5133662

SCHEMBL5133662

COc1cc(O)cc2oc(-c3ccccc3)c(O)c(=O)c12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 2/20 0.73
CYP1A1 P04798 6/20 0.69
CYP1A2 P05177 6/20 0.69
CYP1B1 Q16678 6/20 0.69
MEN1 O00255 6/20 0.69
KMT2A Q03164 6/20 0.69
MAPT P10636 6/20 0.69
ABCB1 P08183 5/20 0.69
CYP3A4 P08684 5/20 0.69
XDH P47989 4/20 0.69
PPARG P37231 4/20 0.69
CA12 O43570 3/20 0.69
CA7 P43166 3/20 0.69
MAOA P21397 3/20 0.69
FTO Q9C0B1 3/20 0.69
CA4 P22748 2/20 0.69
ADORA3 P0DMS8 2/20 0.69
BCHE P06276 2/20 0.69
CYP2D6 P10635 2/20 0.69
CYP2C9 P11712 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15635189 0.91 NOX4 (0.79) NOX4CYP1A1CYP1A2CYP1B1MEN1
SCHEMBL28536757 0.88 ABCG2 (0.83) NOX4CYP1A1CYP1A2CYP1B1MEN1
SCHEMBL38650680 0.88 ABCG2 (0.83) NOX4CYP1A1CYP1A2CYP1B1MEN1
SCHEMBL28664486 0.88 ABCB1 (0.79) NOX4MEN1KMT2AMAPTABCB1
SCHEMBL12640011 0.85 NOX4 (0.79) NOX4CYP1A1CYP1A2CYP1B1MEN1
SCHEMBL21581945 0.85 ABCG2 (0.60) NOX4CYP1A1CYP1A2CYP1B1MEN1
SCHEMBL31675988 0.85 KDM4E (0.67) NOX4CYP1A1CYP1A2CYP1B1MEN1
SCHEMBL4649646 0.85 KDM4E (0.67) NOX4CYP1A1CYP1A2CYP1B1MEN1
SCHEMBL31408172 0.85 NOX4 (1.00) NOX4CYP1A1CYP1A2CYP1B1MEN1
SCHEMBL890990 0.85 NOX4 (1.00) NOX4CYP1A1CYP1A2CYP1B1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530426-B2 Topical use of a UGT inducer-containing composition comprising a dermatologically acceptable carrier to protect and/or enhance the state of the skin/hair and prevent and/or treat imperfections of the skin; flavanoids such as chrysin stimulates isoforms; protective coatings aging/ wrinkling resistance SEDERMA SAS (FR) 2013-09-10 US claimed
CN-107530550-B Light emitting device and cosmetic method for illuminating the skin of a subject by phototherapy 印德尔姆 2021-04-16 CN disclosed
US-10953237-B2 Methods of providing skin care using phototherapy INDERM (FR) 2021-03-23 US disclosed
EP-3271012-B1 DEVICES FOR PROVIDING SKIN CARE USING PHOTOTHERAPY INDERM (FR) 2019-06-19 EP disclosed
US-20180071547-A1 Methods of Providing Skin Care Using Phototherapy INDERM (FR) 2018-03-15 US disclosed
EP-3271012-A1 METHODS OF PROVIDING SKIN CARE USING PHOTOTHERAPY Inderm (FR) 2018-01-24 EP disclosed
CN-107530550-A The method that skin nursing is provided using lucotherapy 印德尔姆 2018-01-02 CN disclosed
EP-1776161-B1 COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER SEDERMA S A S (FR) 2016-10-26 EP disclosed
WO-2016146778-A1 METHODS OF PROVIDING SKIN CARE USING PHOTOTHERAPY INDERM (FR) 2016-09-22 WO disclosed
CN-105106266-A Leontopodium haplophylloides extract and application thereof JALA CORP 2015-12-02 CN disclosed
US-8530426-B2 Topical use of a UGT inducer-containing composition comprising a dermatologically acceptable carrier to protect and/or enhance the state of the skin/hair and prevent and/or treat imperfections of the skin; flavanoids such as chrysin stimulates isoforms; protective coatings aging/ wrinkling resistance SEDERMA SAS (FR) 2013-09-10 US disclosed
US-20080213198-A1 Cosmetic or Dermopharmaceutical Composition Comprising at Least one Udp Glucuronosyl Transferase (Ugt) Enzymes Inducer SEDERMA SAS (FR) 2008-09-04 US disclosed
EP-1776161-A1 COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER Sederma S.A.S. (FR) 2007-04-25 EP disclosed
WO-2005102266-A1 COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER SEDERMA, SAS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080213198-A1 Cosmetic or Dermopharmaceutical Composition Comprising at Least one Udp Glucuronosyl Transferase (Ugt) Enzymes Inducer UGT1A1, UGT1A3, UGDH NOX4 1585/4885CYP1A1 24/4885CYP1A2 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.